§ Mr. DoranTo ask the Secretary of State for Health whether he has received a report of the results of the British multi-centre trials of the drug RU486; and if he will make a statement.
§ Mrs. Virginia BottomleyFor reasons of commercial confidentiality the licensing authority does not disclose342W information about the receipt or progress of applications for permission to conduct clinical trials in patients, or of product licence applications. The result of all clinical trials are required to be submitted when an application for a product licence is made.